Previous Next

2024-02-14

Bispecific antibodies in diffuse large B-cell lymphoma

Oncology

At least a third of patients with diffuse large B-cell lymphoma require a second or even third line of treatment for relapsed or refractory disease. New therapeutic approaches are being developed, such as chemoimmunotherapy and CAR-T-19 cell therapies. CAR-T-19 therapies could provide a cure for 30% to 40% of patients refractory to first-line treatment. But these therapies come up against logistical difficulties (production time, high costs, etc.). Recently, new options have come onto the market: bispecific antibodies such as glofitamab and epcoritamab. More accessible than CAR-T therapy, these bispecific antibodies could prove promising for the treatment of these lymphomas, probably in combination with another therapy.

Source(s) :
Asaad Trabolsi et al. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024 Feb 8;14(1):27. ;

Last press reviews


Traveling to rebuild oneself

By Ana Espino | Published on August 27, 2025 | 2 min read

Can AI save teen lives?

By Ana Espino | Published on August 28, 2025 | 3 min read

Training to save lives

By Ana Espino | Published on August 26, 2025 | 2 min read